Stephen Connelly

Steve is a co-founder, Director and Chief Scientific Officer of Equillium. Prior to co-founding Equillium, Steve was a Principal at BioMed Ventures, a life sciences venture capital group, where he helped manage a venture portfolio of therapeutic, device and diagnostic companies. Steve joined Biomed Ventures from aTyr where he served as Director of Business Development and Therapeutic Alliances and assisted in raising over $150M through private and public financing’s. Prior to aTyr, he was a Senior Scientist at The Scripps Research Institute, where he worked on multiple drug discovery projects spanning different therapeutic areas, including development work with Vyndaqel®, a first-in-class drug approved for the treatment of familial amyloid neuropathy, and a second-generation inhibitor, AG10, currently in development at Eidos Therapeutics for familial amyloid cardiomyopathy. Steve has an extensive track record conducting novel and innovative research and has published over 30 original scientific papers and patents.

Steve received his Bachelor of Science in Medicinal Chemistry and Ph.D. in Biological Chemistry from the University of Exeter, United Kingdom, and Master of Business Administration from the Rady School at University of California, San Diego.